BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16965435)

  • 21. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
    Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
    Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
    [No Abstract]   [Full Text] [Related]  

  • 22. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib.
    Volz HC; Weiss C; Lossnitzer D; Zankl AR; Perz JB; Dengler TJ; Katus HA; Hardt SE
    Int J Cardiol; 2011 Sep; 151(3):e90-2. PubMed ID: 20609486
    [No Abstract]   [Full Text] [Related]  

  • 27. [Two patients with hypereosinophilic syndrome].
    van Ruth S; Lokhorst HM; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2006 May; 150(21):1193-7. PubMed ID: 16768285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
    Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
    Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 30. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
    von Bubnoff N; Gorantla SP; Thöne S; Peschel C; Duyster J
    Blood; 2006 Jun; 107(12):4970-1; author reply 4972. PubMed ID: 16754777
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1-like 1-platelet-derived growth factor receptor alpha fusion gene.
    Thuny C; Gaudy-Marqueste C; Nicol I; Gabert J; Costello R; Grob JJ; Richard MA
    J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):234-5. PubMed ID: 19686260
    [No Abstract]   [Full Text] [Related]  

  • 32. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
    Winter L; Zellweger MJ; Bremerich J
    Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
    [No Abstract]   [Full Text] [Related]  

  • 33. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].
    Qu SQ; Wang Y; Sun XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226
    [No Abstract]   [Full Text] [Related]  

  • 34. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The hypereosinophilic syndrome: idiopathic or not, that is the question.
    Cools J
    Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
    [No Abstract]   [Full Text] [Related]  

  • 37. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
    Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
    Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.